SUN Pharma Philippines Inc. Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: SUN Pharma Philippines Inc. Pharmaceutical Import Records from India — 4 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Pharma Philippines Inc. — Pharmaceutical Importer Profile (2026) | 4 Products, $1.1M Trade | TransData Nexus

SUN Pharma Philippines Inc.

Pharmaceutical Importer · Philippines · Advanced Oncology Focus · $1.1M Total Trade · DGFT Verified

SUN Pharma Philippines Inc. is a pharmaceutical importer based in Philippines with a total trade value of $1.1M across 4 products in 1 therapeutic categories. Based on 21 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SUN Pharma Philippines Inc. sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

SUN Pharma Philippines Inc. — Import Portfolio & Supplier Network

SUN Pharma Philippines Inc. import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Pharma Philippines Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$5.2M	156	100.0%

SUN Pharma Philippines Inc. sources from 1 verified Indian supplier across 119 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Encorate chrono 500 tablets (sodium	$300.0K	6
Caxeta 500 tablets (capecitabine	$200.0K	4
Zosert 50 tablets (sertraline	$195.7K	5
Serotia 200 tablets(quetiapine	$150.0K	3
Dicorate er 500MG tablets Pack	$150.0K	3
Ritemed co-amoxi TAB 625 MG 10'b ph Pack: 10s strip batch: dfg0511a	$103.0K	3
Anarom tablets (anastrozole tablets 1 MG	$100.0K	2
Serotia 25 tablets (quetiapine tablets	$100.0K	2
Sizopin 100 tablets ( clozapine	$100.0K	2
Letroz tablets (letrozole tablets USP 2.	$100.0K	2
Chemodox(doxorubicin hydrochloride	$100.0K	2
Abiraterone tablets USP 250MG	$100.0K	2
Sizodon 2 tablets(risperidone tablets	$93.6K	2
Bortesum INJ 3.5MG 1s vl ph	$88.7K	2
Topirol 50 MG tablets (topiramate	$83.5K	2

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Temozolomide	Advanced Oncology	$350.0K	7	1.5%	12
2	Capecitabine	Advanced Oncology	$300.0K	6	0.3%	14
3	Imatinib	Advanced Oncology	$200.0K	4	0.7%	19
4	Letrozole	Advanced Oncology	$200.0K	4	0.6%	9

SUN Pharma Philippines Inc. imports 4 pharmaceutical products across 1 categories into Philippines totaling $1.1M.

SUN Pharma Philippines Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sun Pharma Philippines, Inc. is a wholly owned subsidiary of Sun Pharma Global FZE, which, in turn, is a subsidiary of Sun Pharmaceutical Industries Limited (Sun Pharma) headquartered in Mumbai, India. Established on December 8, 2011, the company is registered with the Philippine Securities and Exchange Commission (SEC) under SEC Code CS201121379. Its primary business involves the wholesale marketing and distribution of pharmaceutical, cosmetic, and chemical products.

As a subsidiary of Sun Pharma, the largest pharmaceutical company in India and the world's fifth-largest specialty generic pharmaceutical company, Sun Pharma Philippines plays a crucial role in the distribution of Sun Pharma's products within the Philippine market. The company's operations are aligned with Sun Pharma's global mission to provide high-quality, affordable medicines to healthcare professionals and patients worldwide.

2Distribution Network

Sun Pharma Philippines operates from its office located at Unit 604, 6th Floor, Liberty Center Building, 104 H.V. Dela Costa Street, Salcedo Village, Makati City, Metro Manila, 1227. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's affiliation with Sun Pharma, which boasts 43 manufacturing facilities across five continents, suggests a robust distribution network capable of efficiently supplying pharmaceutical products to the Philippine market.

3Industry Role

In the Philippine pharmaceutical supply chain, Sun Pharma Philippines functions as a primary wholesaler and distributor. By importing and distributing finished pharmaceutical formulations from its parent company, Sun Pharma, it ensures the availability of a diverse range of pharmaceutical products in the local market. This role is pivotal in bridging the gap between Sun Pharma's manufacturing capabilities and the needs of healthcare providers and patients in the Philippines.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Pharma Philippines Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sun Pharma Philippines imports finished pharmaceutical formulations exclusively from Sun Pharmaceutical Industries Limited, as evidenced by the total import value of $1.1 million USD across 21 shipments, all sourced from this single supplier. This sourcing strategy indicates a high level of supplier concentration, which can offer benefits such as streamlined logistics and consistent product quality. However, it also presents risks related to supply chain disruptions, currency fluctuations, and potential dependency on a single supplier. The absence of alternative suppliers in the import data suggests a strategic choice to maintain close alignment with the parent company's product offerings and quality standards.

2Supply Chain Resilience

The resilience of Sun Pharma Philippines' supply chain is closely tied to the stability and reliability of Sun Pharmaceutical Industries Limited. Given that all imported products originate from a single supplier, the company may face challenges in mitigating risks associated with supply chain disruptions, such as production delays or geopolitical issues affecting the supplier's operations. The lack of publicly available information on backup suppliers and the diversity of formulations imported suggests a reliance on the parent company's manufacturing capabilities to meet the Philippine market's demands. Ensuring regulatory compliance and maintaining strong communication channels with Sun Pharma are essential for sustaining a resilient supply chain.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, distribution, and marketing of pharmaceutical products. The FDA ensures that all pharmaceutical products meet the required safety, efficacy, and quality standards before they are made available to the public. Key legislation governing pharmaceutical imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which provides the legal framework for the FDA's operations, and the Implementing Rules and Regulations (IRR) of the Food and Drug Administration Act, which detail the procedures for product registration, importation, and distribution.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that all pharmaceutical products imported into the country must be registered with the FDA. This process involves submitting comprehensive documentation, including product information, manufacturing details, and evidence of Good Manufacturing Practice (GMP) compliance. The FDA recognizes GMP certificates from reputable regulatory bodies, such as the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of foreign GMP certifications. Additionally, companies must obtain a License to Operate (LTO) as a drug importer and distributor from the FDA to legally conduct business in the Philippines.

SUN Pharma Philippines Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sun Pharma Philippines focuses on importing and distributing pharmaceutical products in the advanced oncology therapeutic category. The company's top five imported products—Temozolomide, Capecitabine, Imatinib, Letrozole, and an unspecified fifth product—are all used in the treatment of various cancers. This strategic focus aligns with the growing demand for oncology treatments in the Philippines, driven by an increasing incidence of cancer and a need for effective therapies. By concentrating on this therapeutic area, Sun Pharma Philippines aims to address critical healthcare needs and strengthen its position in the market.

2Sourcing Profile

Sun Pharma Philippines' sourcing strategy is centered on importing finished pharmaceutical formulations from Sun Pharmaceutical Industries Limited. This approach ensures consistency in product quality and facilitates the introduction of new products in the Philippine market. The company's portfolio includes a diverse range of formulations, indicating a preference for a comprehensive product offering to meet various patient needs. India's established reputation for producing high-quality generic pharmaceuticals positions it as a strategic partner for Sun Pharma Philippines in fulfilling the Philippine market's demands.

3Market Positioning

Seller's Guide — How to Become a Supplier to SUN Pharma Philippines Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There may be opportunities for new Indian suppliers to enter the Philippine market by offering products that complement Sun Pharma Philippines' existing portfolio, particularly in therapeutic areas not currently covered. Identifying gaps in the current sourcing strategy, such as unmet needs in other therapeutic categories, could present avenues for collaboration. However, establishing relationships with Sun Pharma Philippines would require demonstrating product quality, regulatory compliance, and an understanding of the local market dynamics to effectively meet the needs of the Philippine healthcare system.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Sun Pharma Philippines and the broader Philippine market must ensure their products are registered with the FDA and comply with the FDA's GMP standards. Recognized GMP certifications from reputable regulatory bodies, such as the EMA, WHO, and PIC/S, are essential for facilitating the acceptance of products in the Philippine market. Additionally, exporters must adhere to the FDA's labeling requirements, including providing information in English and Filipino, and comply with serialization mandates to enhance product traceability.

How to Approach

Frequently Asked Questions — SUN Pharma Philippines Inc.

What products does SUN Pharma Philippines Inc. import from India?

SUN Pharma Philippines Inc. imports 4 pharmaceutical products across 1 categories. Top imports: Temozolomide ($350.0K), Capecitabine ($300.0K), Imatinib ($200.0K), Letrozole ($200.0K).

Who supplies pharmaceuticals to SUN Pharma Philippines Inc. from India?

SUN Pharma Philippines Inc. sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $5.2M).

What is SUN Pharma Philippines Inc.'s total pharmaceutical import value?

SUN Pharma Philippines Inc.'s total pharmaceutical import value from India is $1.1M, based on 21 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Pharma Philippines Inc. focus on?

SUN Pharma Philippines Inc. imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full SUN Pharma Philippines Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.